Skip to main content

Table 4 Association of high-risk interactive genotypes with platelet aggregation and clinical outcomes

From: Variants in clopidogrel-relevant genes and early neurological deterioration in ischemic stroke patients receiving clopidogrel

 patients carrying the high-risk interactive genotypes (n = 87)patients carrying the low-risk interactive genotypes (n = 288)p value
AA-induced platelet aggregation (%)
 before clopidogrel85.3 ± 14.871.2 ± 17.4< 0.001
 after 7–10 days clopidogrel55.5 ± 12.635.3 ± 14.9< 0.001
 inhibition30.2 ± 9.238.1 ± 11.4< 0.001
ADP-inducedplatelet aggregation (%)
 Before clopidogrel79.1 ± 16.267.9 ± 14.8< 0.001
 after 7–10 days clopidogrel45.2 ± 13.225.6 ± 8.6< 0.001
 inhibition34.9 ± 12.346.4 ± 13.6< 0.001
END (n, %)34 (39.1)61 (21.2)< 0.001
RIS (n, %)1 (1.1)2 (0.7)0.963
MI (n, %)0 (0.0)1 (0.3)0.586
Death (n, %)1 (1.1)1 (0.3)0.754
Safety outcomes
 Asymptomatic HT (n, %)1 (1.1)6 (2.1)0.438
 Asymptomatic ICH (n, %)1 (1.1)1 (0.3)0.754
 Extracranial bleeding (n, %)2 (2.3)9 (3.1)0.443
  1. AA arachidonic acid, ADP adenosine diphosphate, END early neurological deterioration, MI myocardial infarction, RIS recurrent ischemic stroke, HT hemorrhagic transformation, ICH intracerebral hemorrhage